• undefined
      • undefined
    1. Home
    2. People
    3. Gatof, Jake

    Jake Gatof

    Partner

    Boston

    Jake Gatof is a trusted advisor to high-growth life sciences and technology companies—as well as the investors who back them—guiding them through every stage of their journey, from formation to strategic exit.

    Jake counsels visionary founders and top-tier venture and growth equity funds on venture financings, complex M&A, corporate governance, strategic collaborations, and other mission-critical transactions. Known for his steady counsel and deep market knowledge, Jake helps emerging companies scale with confidence and investors deploy capital with clarity.

    Jake’s experience also includes representation of top growth equity and venture capital funds in the execution of their deals and deployment of capital, including work with TPG Capital, 5AM Ventures, and Pillar VC, among others.

    He is currently a member of the Board of Trustees for the Leukemia and Lymphoma Society (New England) and is an active member of the Boston venture and emerging company ecosystem, including frequent speaking engagements for founders and other stakeholders on entrepreneurship, capital formation, and strategic transaction matters.

    Prior to joining Orrick, Jake worked with Wilson Sonsini Goodrich & Rosati in its Boston office upon its founding. He lives in Boston with his wife Emily, an oncologist here in Boston, and their daughter Mia.

      • Matterworks in its Series A financing led by Lewis & Clark Partners and OMX Ventures
      • NTx in its $47.5M Series B financing led by RA Capital
      • Iterative Scopes in multiple rounds of financing, including its $150M Series B financing co-led by Insight Partners and Clearlake
      • Lexent Bio in its acquisition by Foundation Medicine (member of the Roche Group)
      • Clear Future on acquisition of FC2 business
      • IVIVA in its sale to United Therapeutics
      • 4me on strategic growth investment
      • GI Windows in its $16.4M Series A-1 Financing by Johnson & Johnson Innovation (JJDC, Inc.), Sonder Capital, GT Healthcare, JC Investco, and one other strategic investor
      • Elucidata on $16M Series A financing
      • VitroLabs in its $46M Series A financing led by Agronomics
      • Vesigen in its launch and $28.5M Series A financing led by Morningside Ventures and Leaps by Bayer
      • Libra Therapeutics in its launch and $29M Series A led by Boehringer Ingelheim Venture Fund, Epidarex Capital, and Santé
      • TigaTx in multiple rounds of financing and its sale to Epsilogen

      Includes matters handled prior to joining Orrick